![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Rygiel Tomasz P Luijk Bart Meyaard Linde
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.23, Iss.3, 2013-03, pp. : 389-392
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Therapeutic compounds: patent evaluation of WO2011011652A1
Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 9, 2011-09 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Antagonists of IL-1R: a patent evaluation (WO2012122985)
Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 7, 2013-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Anti-CD20 Antibody in Primary Sjogren’s Syndrome Management
Current Pharmaceutical Biotechnology, Vol. 15, Iss. 6, 2014-06 ,pp. :